Government in no rush to grant 'compulsory licences'

Amid suggestions to use the tool for Remdisivir and Tocilizumab, two drugs that are being used, government sources said that it made little sense to invoke compulsory licensing provisions, given that the active pharmaceutical ingredient (API) is not available in the country.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/2PVBLqH
via IFTTT